Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07PML
|
|||
| Drug Name |
Ublituximab + umbralisib
|
|||
| Indication | Chronic lymphocytic leukaemia [ICD-11: 2A82.0; ICD-10: C83.0, C91.1] | Phase 3 | [1] | |
| Non-hodgkin lymphoma [ICD-11: 2B33.5; ICD-10: C85.9] | Phase 2/3 | [1] | ||
| Company |
TG Therapeutics New York, NY
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Leukocyte surface antigen Leu-16 (CD20) | Target Info | . | [1] |
| KEGG Pathway | Hematopoietic cell lineage | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.